Cargando…
Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells
Immune checkpoint inhibitors (ICI) widely improved the treatment of solid and hematologic malignancies. Yet, a remarkable proportion of patients receiving ICI develop immune related adverse events (irAEs) which are difficult to define as treatment-related. This underlines the need to develop a bioma...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808779/ https://www.ncbi.nlm.nih.gov/pubmed/36605194 http://dx.doi.org/10.3389/fimmu.2022.1082084 |